Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant (Q43106547)

14 November 2017

title

Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant (English)

1 reference

14 November 2017

P Hoever

1

1 reference

14 November 2017

S de Haas

2

1 reference

14 November 2017

J Winkler

3

1 reference

14 November 2017

R C Schoemaker

4

1 reference

14 November 2017

E Chiossi

5

1 reference

14 November 2017

J van Gerven

6

1 reference

14 November 2017

J Dingemanse

7

1 reference

14 November 2017

language of work or name

English

0 references

publication date

7 April 2010

1 reference

Clinical Pharmacology & Therapeutics

14 November 2017

published in

1 reference

14 November 2017

volume

87

1 reference

14 November 2017

issue

5

1 reference

14 November 2017

page(s)

593-600

1 reference

https://scigraph.springernature.com/pub.10.1038/clpt.2010.19

14 November 2017

exact match

0 references

cites work

The whats and whens of sleep-dependent memory consolidation.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Sleep benefits subsequent hippocampal functioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Sleep enhances the human antibody response to hepatitis A vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Sleep function: current questions and new approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Sleep in the intensive care unit setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Role of GABAA receptors in the physiology and pharmacology of sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Zolpidem-induced amnesia and somnambulism: rare occurrences?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Use of computerized dynamic posturography to assess balance in older adults after nighttime awakenings using zolpidem as a reference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

The hypocretin/orexin receptor: therapeutic prospective in sleep disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

The hypocretins/orexins: novel hypothalamic neuropeptides involved in different physiological systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Protein splicing of inteins and hedgehog autoproteolysis: structure, function, and evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Biomedical application of orexin/hypocretin receptor ligands in neuroscience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Promotion of sleep by targeting the orexin system in rats, dogs and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

The effects of benzodiazepine (triazolam), cyclopyrrolone (zopiclone) and imidazopyridine (zolpidem) hypnotics on the frequency of hippocampal theta activity and sleep structure in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Hypocretin/Orexin: a molecular link between sleep, energy regulation, and pleasure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Saccades and pursuit: two outcomes of a single sensorimotor process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Pharmacokinetic-pharmacodynamic modeling of midazolam effects on the human central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Pseudohallucinations after zolpidem intake: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Central nervous system side effects associated with zolpidem treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Comparative pharmacodynamics of Ro 41-3696, a new hypnotic, and zolpidem after night-time administration to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Specific effects of an amnesic drug: effect of lorazepam on study time allocation and on judgment of learning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

The pharmacokinetic and pharmacodynamic effects of SL65.1498, a GABA-A alpha2,3 selective agonist, in comparison with lorazepam in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Human performance after a barbiturate (heptabarbitone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

Banking sleep: realization of benefits during subsequent sleep restriction and recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

7 January 2021

Advances in the management of insomnia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

7 January 2021

Effects of intravenous temazepam. I. Saccadic eye movements and electroencephalogram after fast and slow infusion to pseudo steady state

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

7 January 2021

The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

7 January 2021

The use of analogue scales in rating subjective feelings

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2010.19

7 January 2021

Identifiers

DOI

10.1038/CLPT.2010.19

1 reference

Dimensions Publication ID

14 November 2017

1047854063

0 references

1 reference